We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

57 hedge funds and large institutions have $83.2M invested in ImmunityBio in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 11

118% more call options, than puts

Call options by funds: $480K | Put options by funds: $220K

0.95% more ownership

Funds ownership: 18.16% → 19.11% (+0.95%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

2% less funds holding

Funds holding: 58 → 57 (-1)

27% less capital invested

Capital invested by funds: $113M → $83.2M (-$30.1M)

Holders
57
Holders Change
-1
Holders Change %
-1.72%
% of All Funds
1.42%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
24
Reduced
11
Closed
6
Calls
$480K
Puts
$220K
Net Calls
+$260K
Net Calls Change
+$809K

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$765K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$677K
3
Renaissance Technologies
Renaissance Technologies
New York
+$614K
4
HK
Horizon Kinetics
New York
+$430K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$331K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$792K
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$632K
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$380K
4
PPA
Parametric Portfolio Associates
Washington
-$197K
5
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$180K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$243K +$54.7K +8,874 +25%
Goldman Sachs
27
Goldman Sachs
New York
$237K -$55.2K -8,951 -17%
Millennium Management
28
Millennium Management
New York
$198K -$11.6K -1,883 -5%
RhumbLine Advisers
29
RhumbLine Advisers
Massachusetts
$192K +$1.36K +220 +0.6%
Deutsche Bank
30
Deutsche Bank
Germany
$170K -$46.7K -7,575 -19%
ARTA
31
A.R.T. Advisors
New York
$154K +$174K +28,244 New
Barclays
32
Barclays
United Kingdom
$145K +$6.85K +1,112 +4%
CS
33
Credit Suisse
Switzerland
$142K +$41.5K +6,740 +35%
JP Morgan Chase
34
JP Morgan Chase
New York
$140K -$792K -128,556 -83%
Russell Investments Group
35
Russell Investments Group
United Kingdom
$139K +$156K +25,320 New
Wells Fargo
36
Wells Fargo
California
$138K +$25.6K +4,161 +20%
AIG
37
American International Group
New York
$112K +$9.44K +1,532 +8%
Manulife (Manufacturers Life Insurance)
38
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$111K -$45.9K -7,444 -27%
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$106K – – –
NFA
40
Nationwide Fund Advisors
Ohio
$95K – – –
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$93K – – –
VOYA Investment Management
42
VOYA Investment Management
Georgia
$74K – – –
ADL
43
Asset Dedication LLC
California
$72K – – –
UBS Group
44
UBS Group
Switzerland
$62K +$13.2K +2,138 +23%
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$61K +$37.9K +6,157 +125%
Simplex Trading
46
Simplex Trading
Illinois
$56K +$64K +10,390 New
EWM
47
Edge Wealth Management
New York
$55K +$61.6K +10,000 New
Legal & General Group
48
Legal & General Group
United Kingdom
$27K – – –
Bank of Montreal
49
Bank of Montreal
Ontario, Canada
$19K -$162K -26,291 -88%
Citigroup
50
Citigroup
New York
$18K +$12.7K +2,061 +173%
1
2
3

IBRX Hedge Fund Activity: Q3 2017 in Review

57 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2017, worth a combined $83.2M — down 27% from $113M a quarter earlier.

Fund positioning in IBRX was balanced in Q3 2017: 6 funds opened new positions, 6 closed out, 24 added to existing stakes and 11 trimmed.

The largest buyer was Invesco, adding an estimated $765K. The largest seller was JP Morgan Chase, cutting an estimated $792K.

  • 57 institutional investors held ImmunityBio (IBRX) as of Q3 2017, down from 58 in Q2 2017.
  • Funds reported $83.2M of ImmunityBio stock for Q3 2017, down 27% quarter-over-quarter.
  • 6 funds opened new ImmunityBio positions in Q3 2017 and 6 closed out, a net change of 0 holders.
  • The largest ImmunityBio buyer in Q3 2017 was Invesco, an estimated $765K added.
  • The largest ImmunityBio seller in Q3 2017 was JP Morgan Chase, an estimated $792K sold.

Based on aggregated 13F filings for Q3 2017.